NCT03131206 - A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 19, 2017

Primary Completion Date

November 8, 2018

Study Completion Date

April 8, 2019

Conditions

ALK-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Non-small Cell Lung Cancer (NSCLC)RET-positive Thyroid Cancer

Interventions

DRUG

Alectinib

"* Oral, BID~* Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.~* Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days."

Trial Locations (4)

92697-7600

University of California, Irvine, Irvine

02115

Beth Israel Deaconess Medical Center, Boston

Brigham and Women's Hospital, Boston

02215

Dana Farber Cancer Institute, Boston